Factors guiding the choice of delivery device for inhaled corticosteroids in the long-term management of stable asthma and COPD: Focus on budesonide

Respiratory Medicine

Volumn 99, Issue 7, 2005, Pages 836-849

  Thorsson, Lars ^a   Geller, David ^b  

^a ASTRAZENECA R AND D   (Sweden)

^b NEMOURS CHILDREN S HOSPITAL   (United States)

Author keywords

Asthma; Budesonide; COPD; Delivery devices; Inhaled corticosteroids

Indexed keywords

BECLOMETASONE; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE; PLACEBO;

ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DEVICE; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; GINGIVA DISEASE; HOARSENESS; HUMAN; INHALATION SPACER; LONG TERM CARE; METERED DOSE INHALER; NEBULIZER; PATIENT CARE; POWDER INHALER; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; REVIEW; SORE THROAT; THRUSH;

EID: 20444429757     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2005.02.012     Document Type: Article

References (83)

1. World Health Organization World Health Organization fact sheet Indian J Chest Dis Allied Sci 42 2000 126-128
2. International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC Lancet 351 1998 1225-1232
3. Childhood Asthma Management Program Research Group Long-term effects of budesonide or nedocromil in children with asthma N Engl J Med 343 2000 1054-1063
4. National Institutes of Health: National Heart, Lung, and Blood Institute, Global Initiative for Asthma. Global strategy for asthma management and prevention. Bethesda, MA: National Institutes of Health, Publication No. 02-3659; 2002.
5. K.M. Hvizdos B. Jarvis Budesonide inhalation suspension: A review of its use in infants, children and adults with inflammatory respiratory disorders Drugs 60 2000 1141-1178
6. C.L. Leach P.J. Davidson B.E. Hasselquist R.J. Boudreau Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone. A cross-over study in healthy volunteers Chest 122 2002 510-516
7. L. Borgström On the use of dry powder inhalers in situations perceived as constrained J Aerosol Med 14 2001 281-287
8. E. Derom L. Thorsson Factors affecting the clinical outcome of aerosol therapy In: H. Bisgaard C. O'Callaghan G.C. Smaldone editors. Drug delivery to the lung 2002 Marcel Dekker Basel 143-164
9. M.B. Dolovich Aerosol delivery devices and airways/lung deposition In: R.P. Schleimer P.M. O'Byrne S.J. Szefler R. Brattsand editors. Inhaled steroids in asthma 2002 Marcel Dekker Basel 169-212
10. 2-agonist and anticholinergic aerosols in patients with severe airflow obstruction Thorax 51 1996 977-980
11. B. Olsson Aerosol particle generation from dry powder inhalers: Can they equal pressurized metered dose inhalers? J Aerosol Med 8 Suppl. 3 1995 S13-S19
12. L. Borgström Local versus total systemic bioavailability as a means to compare different inhaled formulations of the same substance J Aerosol Med 11 1998 55-63
13. K. Dahlström L. Thorsson P. Larsson K. Nikander Systemic availability and lung deposition of budesonide via three different nebulizers in adults Ann Allergy Asthma Immunol 90 2003 226-232
14. L. Thorsson S. Edsbäcker T-B. Conradson Lung deposition of budesonide from Turbuhaler® is twice that from a pressurized metered-dose inhaler P-MDI Eur Respir J 7 1994 1839-1844
15. L. Thorsson S. Edsbäcker Lung deposition of budesonide from a pressurized metered-dose inhaler attached to a spacer Eur Respir J 12 1998 1340-1345
16. L. Thorsson S. Edsbäcker A. Källén C.-G. Löfdahl Pharmacokinetics and systemic activity of fluticasone propionate and budesonide Br J Clin Pharmacol 52 2001 1-15
17. L. Borgström E. Bondesson F. Moren E. Trofast S.P. Newman Lung deposition of budesonide inhaled via Turbuhaler: A comparison with terbutaline sulphate in normal subjects Eur Respir J 7 1994 69-73
18. L. Agertoft S. Pedersen Lung deposition and systemic availability of fluticasone Diskus and budesonide Turbuhaler in children Am J Respir Crit Care Med 168 2003 779-782
19. L. Thorsson C. Kenyon S.P. Newman L. Borgström Lung deposition of budesonide in asthmatics: A comparison of different formulations Int J Pharm 168 1998 119-127
20. J.H. Toogood F.A. White J.C. Baskerville L.J. Fraher B. Jennings Comparison of the antiasthmatic, oropharyngeal, and systemic glucocorticoid effects of budesonide administered through a pressurized aerosol plus spacer or the Turbuhaler dry powder inhaler J Allergy Clin Immunol 99 1997 186-193
21. L. Agertoft S. Pedersen Importance of the inhalation device on the effect of budesonide Arch Dis Child 69 1993 130-133
22. C.J. Kenyon L. Thorsson L. Borgstrom S.P. Newman The effects of static charge in spacer devices on glucocorticosteroid aerosol deposition in asthmatic patients Eur Respir J 11 1998 606-610
23. S.G. Devadason T. Huang S. Walker R. Troedson P.N. Le Souef Distribution of technetium-99m-labelled QVAR delivered using an Autohaler device in children Eur Respir J 21 2003 1007-1011
24. L. Agertoft A. Andersen E. Weibull S. Pedersen Systemic availability and pharmacokinetics of nebulised budesonide in preschool children Arch Dis Child 80 1999 241-247
25. M. Dahlbäck Behaviour of nebulizing solutions and suspensions J Aerosol Med 7 Suppl. 1994 S13-S18
26. M. Keller J. Jauernig F.C. Lintz M. Knoch Nebulizer nanosuspensions: important device and formulation interactions Respir Drug Delivery VIII 1 2002 197-206
27. G.C. Smaldone M. Cruz-Rivera K. Nikander In vitro determination of inhaled mass and particle distribution for budesonide nebulizing suspension J Aerosol Med 11 1998 113-125
28. K. Nikander M. Turpeinen P. Wollmer The conventional ultrasonic nebulizer proved inefficient in nebulizing a suspension J Aerosol Med 12 1999 47-53
29. K. Nikander L. Agertoft S. Pedersen Breath-synchronized nebulization diminishes the impact of patient-device interfaces (facemask or mouthpiece) on the inhaled mass of nebulized budesonide J Asthma 37 2000 451-459
30. M. Mellon J. Leflein K. Walton-Bowen M. Cruz-Rivera S. Fitzpatrick J.A. Smith Comparable efficacy of administration with face mask or mouthpiece of nebulized budesonide suspension for infants and young children with persistent asthma Am J Respir Crit Care Med 162 2000 593-598
31. L. Borgström E. Derom E. Ståhl E. Wåhlin-Boll R. Pauwels The inhalation device influences lung deposition and bronchodilating effect of terbutaline Am J Respir Crit Care Med 153 1996 1636-1640
32. R. Pauwels S. Newman L. Borgström Airway deposition and airway effects of anti-asthma drugs delivered from metered-dose inhalers Eur Respir J 10 1997 2127-2138
33. L. Agertoft S. Pedersen Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children Respir Med 88 1994 373-381
34. G. Gross P.J. Thompson P. Chervinsky J. Vanden Burgt Hydrofluoroalkane-134a beclomethasone dipropionate 400 μg is as effective as chlorofluorocarbon beclomethasone dipropionate 800 μg for the treatment of moderate asthma Chest 115 1999 343-351
35. H. Bisgaard K. Nikander E. Munch Comparative study of budesonide as a nebulized suspension vs metered-dose inhaler in adult asthmatics Respir Med 92 1998 44-49
36. P. Gustafsson H. Andersson M. Glad B. Johal P.K.P. Brunell Comparison of total and fine particle mass generated from two dry powder inhalers (DPIs) by 4-year old children with asthma Eur Respir J 2002 P2725 [abstract]
37. Thorsson L, Edsbäcker S. Less variability in lung deposition of budesonide via Turbuhaler than of fluticasone via Diskus/Accuhaler® and pMDI in adults. Presented at ERS 2003, D035 [Poster: C60].
38. P.H. Brown A.C.W.S. Ning A.P. Greening A. McLean S. Crowley G.K. Crompton Peak inspiratory flow through Turbuhaler® in acute asthma Eur Respir J 8 1995 1940-1941
39. E. Ståhl L.B. Ribeiro G. Sandahl Dose response to inhaled terbutaline powder and peak inspiratory flow through Turbuhaler® in children with mild to moderate asthma Pediatr Pulmonol 22 1996 106-110
40. M. Dewar A. Jamieson A. McLean G. Crompton Peak inspiratory flow through Turbuhaler in chronic obstructive airways disease Respir Med 93 1999 342-344
41. L. Agertoft S. Pedersen K. Nikander Drug delivery from the Turbuhaler and Nebuhaler pressurized metered dose inhaler to various age groups of children with asthma J Aerosol Med 12 1999 161-169
42. J. Anhøj L. Thorsson H. Bisgaard Lung deposition of inhaled drugs increases with age Am J Respir Crit Care Med 162 2000 1819-1822
43. J.H. Wildhaber S.G. Devadason J.M. Wilson et al. Lung deposition of budesonide from Turbuhaler in asthmatic children Eur J Pediatr 157 1998 1017-1022
44. T. Engel J.H. Heinig H.J. Malling B. Scharling K. Nikander F. Madsen Clinical comparison of inhaled budesonide delivered either via pressurized metered dose inhaler or Turbuhaler Allergy 44 1989 220-225
45. L. Hetta L-G. Larsson K. Nikander A comparative clinical study of inhaled budesonide delivered either via pressurized metered dose inhaler or via Turbuhaler Eur Respir J 2 Suppl. 8 1989 832S
46. H.E.J. Sinninghe Damsté P. Oostinga A. Heeringa A clinical comparison of inhaled budesonide administered either via a metered dose inhaler or via Turbuhaler Eur Respir J 2 Suppl. 8 1989 44S
47. S.D. Gunn M. Choudhury K. Au R.J. Burnett H.L. Black M.L. Turbitt Inhaled steroid treatment reduction in stable asthmatics: A comparison of beclomethasone/budesonide metered dose inhaler with half dose treatment using budesonide Turbuhaler, given once or twice daily Eur J Clin Res 7 1997 1-14
48. T. Haahtela M. Järvinen T. Kava K. Kiviranta S. Koskinen K. Lehtonen et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma N Engl J Med 331 1994 700-705
49. O. Selroos R. Backman K-O. Forsén et al. Local side-effects during 4-year treatment with inhaled corticosteroids - a comparison between pressurized metered-dose inhalers and Turbuhaler® Allergy 49 1994 888-890
50. J. Boe G. Stiksa K. Svensson E. Asbrink New method of evaluating patient preference for different inhalation delivery systems Ann Allergy 68 1992 255-260
51. J.W. Baker M. Mellon J. Wald M. Welch M. Cruz-Rivera K. Walton-Bowen A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants Pediatrics 103 1999 414-421
52. J.P. Kemp D.P. Skoner S.J. Szefler K. Walton-Bowen M. Cruz-Rivera J.A. Smith Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children Ann Allergy Asthma Immunol 83 1999 231-239
53. M.B. Scott M.H. Ellis M. Cruz-Rivera S. Fitzpatrick J.A. Smith Once-daily budesonide inhalation suspension in infants and children <4 and ≥4 years of age with persistent asthma Ann Allergy Asthma Immunol 87 2001 488-495
54. G. Shapiro L. Mendelson M.J. Kraemer M. Cruz-Rivera K. Walton-Bowen J.A. Smith Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid-dependent, persistent asthma J Allergy Clin Immunol 102 1998 789-796
55. J. Leflein J. Baker K. Walton-Bowen S. Fitzpatrick J. Smith M. Cruz-Rivera Budesonide inhalation suspension (BIS) is more effective than cromolyn sodium (Intal) in controlling asthma over 52 weeks in young children with persistent asthma J Allergy Clin Immunol 105 Suppl., Part 2 2000 S261
56. S.P. Newman Turbuhaler, an inspiratory flow driven inhaler: Chairman's introduction. Part 2 J Aerosol Med 7 Suppl. 1 1994 S41
57. D.B. Allen Safety of inhaled corticosteroids in children Pediatr Pulmonol 33 2002 208-220
58. B.J. Lipworth Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis Arch Intern Med 159 1999 941-955
59. B.J. Lipworth A.M. Wilson Dose-response to inhaled corticosteroids: benefits and risks Semin Respir Crit Care Med 19 1998 625-646
60. T.L. Randell K.C. Donaghue G.R. Ambler C.T. Cowell D.A. Fitzgerald P.P. van Asperen Safety of the newer inhaled corticosteroids in childhood asthma Paediatr Drugs 5 2003 481-504
61. M.B. Scott D.P. Skoner Short-term and long-term safety of budesonide inhalation suspension in infants and young children with persistent asthma J Allergy Clin Immunol 104 1999 200-209
62. L. Agertoft S. Pedersen Bone mineral density in children with asthma receiving long-term treatment with inhaled budesonide Am J Respir Crit Care Med 157 1998 178-183
63. L. Agertoft S. Pedersen Effect of long-term treatment with inhaled budesonide on adult height in children with asthma N Engl J Med 343 2000 1064-1069
64. R.A. Pauwels S. Pedersen W.W. Busse et al. Early intervention with budesonide in mild persistent asthma: A randomised double-blind trial Lancet 361 2003 1071-1075
65. S. Pedersen Do inhaled corticosteroids inhibit growth in children? Am J Respir Crit Care Med 164 2001 521-535
66. B.J. Lipworth Airway and systemic effects of inhaled corticosteroids in asthma: Dose-response relationship Pulm Pharmacol 9 1996 19-27
67. J.S. Larsen M. Hahn B. Ekholm K.A. Wick Evaluation of conventional press-and-breathe metered-dose inhaler technique in 501 patients J Asthma 31 1994 193-199
68. G.G. Guidry W.D. Brown S.W. Stogner R.B. George Incorrect use of metered dose inhalers by medical personnel Chest 101 1992 31-33
69. M. Molimard C. Raherison S. Lignot F. Depont A. Abouelfath N. Moore Assessment of handling of inhaler devices in real life: An observational study in 3811 patients in primary care J Aerosol Med 16 2003 249-254
70. R.J. Scarfone G.A. Capraro J.J. Zorc H. Zhao Demonstrated use of metered-dose inhalers and peak flow meters by children and adolescents with acute asthma exacerbations Arch Pediatr Adolesc Med 156 2002 378-383
71. L. Borgström T. Bengtsson E. Derom R. Pauwels Variability in lung deposition of inhaled drug, within and between asthmatic patients, with a pMDI and a dry powder inhaler, Turbuhaler Int J Pharm 193 2000 227-230
72. R. Iles P. Lister A.T. Edmunds Crying significantly reduces absorption of aerosolised drug in infants Arch Dis Child 81 1999 163-165
73. G. Murakami T. Igarashi Y. Adachi et al. Measurement of bronchial hyperreactivity in infants and preschool children using a new method Ann Allergy 64 1990 383-387
74. A. Tal H. Golan N. Grauer M. Aviram D. Albin M.R. Quastel Deposition pattern of radiolabeled salbutamol inhaled from a metered-dose inhaler by means of a spacer with mask in young children with airway obstruction J Pediatr 128 1996 479-484
75. H.M. Janssens E.M. Heijnen V.M. de Jong et al. Aerosol delivery from spacers in wheezy infants: A daily life study Eur Respir J 16 2000 850-856
76. I. Amirav M.T. Newhouse Aerosol therapy with valved holding chambers in young children: Importance of the facemask seal Pediatrics 108 2001 389-394
77. J.E. Esposito-Festen B. Ates F.J.M. Van Vliet A.F.M. Verbraak J.C. De Jongste H.A.W.M. Tiddens Effect of a facemask leak on aerosol delivery from a pMDI-spacer system J Aerosol Med 17 2004 1-6
78. M.L. Everard A.R. Clark A.D. Milner Drug delivery from jet nebulisers Arch Dis Child 67 1992 586-591
79. D.E. Geller K.C. Kesser H.M. Janssens H.A. Tiddens Delivery of budesonide inhalation suspension (BIS) through an infant upper airway model Am J Respir Crit Care Med 167 2003 A508
80. H.M. Janssens E.C. van der Wiel A.F. Verbraak J.C. de Jongste P.J. Merkus H.A. Tiddens Aerosol therapy and the fighting toddler: Is administration during sleep an alternative? J Aerosol Med 16 2003 395-400
81. I. Amirav I. Balanov M. Gorenberg D. Groshar A.S. Luder Nebuliser hood compared to mask in wheezy infants: Aerosol therapy without tears! Arch Dis Child 88 2003 719-723
82. D.E. Geller B. Kesser Blowby vs face mask for nebulized drugs in young children J Allergy Clin Immunol 2004 [abstract]
83. S. Sangwan B.K. Gurses G.C. Smaldone Facemasks and facial deposition of aerosols Pediatr Pulmonol 37 2004 447-452